Overview of Ibupirac Flex

Quick Facts

Property	Description
Active Ingredients	Ibuprofen and Chlorzoxazone
Form	Film-coated tablet (oral administration)
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID) and Skeletal Muscle Relaxant
Common Use	Management of acute musculoskeletal pain and spasm
Origin	Synthetic

Composition and Classification of Ibupirac Flex

Ibupirac Flex is a recognized fixed-dose combination product containing the active ingredients Ibuprofen and Chlorzoxazone, typically prepared for oral administration as a film-coated tablet. This medicine is entirely synthetic in origin and is defined by the concurrent inclusion of two distinct compounds that address symptoms through different pathways.

Ibuprofen, a propanoic acid derivative, is classified pharmacologically as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a class clinically recognized for its anti-inflammatory effects and ability to reduce pain. Chlorzoxazone belongs to the class of Centrally-Acting Skeletal Muscle Relaxants, which operate by affecting nerve signals in the spinal cord and brain. This combination product is positioned for use by adult patients experiencing acute pain, distinguishing it from products marketed solely for general aches or fever.

Pharmacological Identity and Dual Therapeutic Action

The primary pharmacological identity of this medicine is defined by its dual capacity to function as both an anti-inflammatory analgesic and a muscle relaxant. This synergy is specifically designed for integrated management of conditions characterized by both pain and involuntary muscle tightness, such as acute pain following a muscle strain.

This pairing creates a dual therapeutic action that contrasts with treatments utilizing only a pure NSAID or a simple analgesic. The product's overall general purpose is to provide relief from acute painful scenarios in musculoskeletal disorder treatment where inflammation contributes to the pain while muscle spasm or rigidity exacerbates the discomfort. By incorporating the muscle relaxant, the medicine targets a complex pain syndrome more comprehensively than either component could achieve independently.

Regulatory References

MedlinePlus: Ibuprofen

What side effects are possible with Ibupirac Flex?

Possible Side Effects and Safety Information

This section describes the officially documented adverse effects and safety characteristics of the combination of Ibuprofen (NSAID) and Chlorzoxazone (Skeletal Muscle Relaxant), as classified by global regulatory authorities.

Adverse Reaction Classification

Side effects are categorized by frequency and the body system affected (System-Organ-Class or SOC). Common adverse reactions typically include Gastrointestinal Disorders such as dyspepsia, nausea, vomiting, and diarrhea. Nervous System Disorders like dizziness, drowsiness, and headache are also frequently listed, primarily due to the muscle relaxant component.

Classification	Common Examples (SOC)
Common	Dyspepsia, Drowsiness, Nausea, Dizziness
Rare	Gastrointestinal Bleeding, Hepatotoxicity, Blood Dyscrasias

Serious Safety Information

Regulatory labeling highlights risks of serious but less frequent adverse reactions. The Ibuprofen component is associated with an increased risk of serious Cardiovascular Thrombotic Events (including myocardial infarction and stroke) and severe Gastrointestinal Bleeding or perforation, which can be fatal. The Chlorzoxazone component carries a specific risk of rare but serious Hepatocellular Toxicity (liver damage). Serious skin reactions, such as Stevens-Johnson Syndrome (SJS), have also been documented.

Population and Duration Safety Patterns

The risk profile varies based on patient characteristics and exposure. Older adults generally have a higher frequency of adverse reactions, particularly severe gastrointestinal events. Furthermore, the risk of serious cardiovascular events may increase with the duration of use. Use is formally contraindicated in patients with pre-existing conditions such as severe heart failure, active gastrointestinal ulceration, or severe renal or hepatic failure, as stated in official product information.

Overdose and Emergency Response

The official regulatory documents detailing overdose for the combination of Ibuprofen and Chlorzoxazone focus on potential toxicity involving the Central Nervous System (CNS), respiratory, and vital organ systems. Documented overdose presentations include Gastrointestinal disturbances such as nausea, vomiting, severe abdominal pain, and diarrhea. CNS effects may manifest as drowsiness, dizziness, severe headache, and unsteadiness.

In severe overdose situations, life-threatening manifestations may occur. These include profound CNS depression (leading to decreased level of consciousness or coma), respiratory depression, severe hypotension (shock), and cardiovascular instability. The risk of acute organ damage is also documented, involving severe Gastrointestinal Bleeding and Acute Renal Failure.

SEEK IMMEDIATE MEDICAL ATTENTION for any suspected overdose. Emergency medical care and hospital observation are required following any acute ingestion of excessive amounts. This action is mandated due to the potential for serious complications. Management is entirely symptomatic and supportive, as no specific antidote is known.

Officially described supportive measures include gastric decontamination, monitoring of vital signs, and required clinical observation to assess for complications like metabolic acidosis or delayed organ injury. The official profile notes a risk of chronic liver or kidney injury following recovery from very large ingestions.

Therapeutic Uses of Ibupirac Flex

What Ibupirac Flex Treats: Main Uses and Benefits

Ibupirac Flex is a combination medication intended for the symptomatic relief of mild to moderate acute pain associated with musculoskeletal conditions that involve muscle spasms or contractures.

The therapeutic intent of this product is to address the discomfort and limited function that may arise from these conditions.

Quick Facts on Therapeutic Domains

Targeted Symptoms: Helps with the management of pain and discomfort related to muscle tension.
Associated Conditions: Used for relief of symptoms tied to musculoskeletal pain with accompanying muscle contractures or spasm.
Primary Benefit: The combination of ingredients contributes to the relief of pain and eases muscle tension in the affected area.

This medication is typically reserved for short-term use as an adjunct to rest and other physical therapies, based on a healthcare professional's therapeutic overview. Its intended purpose is to provide temporary relief of symptoms while the underlying condition is being managed. It is considered part of the treatment regimen for these specific indications.

Regulatory References

NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility for Ibupirac Flex: Official Regulatory Status

The Ibuprofen-Chlorzoxazone combination product is designated for use primarily by adult patients. Official regulatory documents define eligibility through strict classifications that mandate who must not use the medicine and who requires conditional use based on specific health status or age.

Regulatory Status	Affected Population or Condition
Contraindicated (Must Not Use)	Third trimester of pregnancy, severe cardiac, hepatic, or renal failure, active gastrointestinal (GI) bleeding or recurrent peptic ulcers, and known hypersensitivity to the components or other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). Prohibited for perioperative pain following CABG surgery.
Use Not Recommended	Pediatric patients (safety and efficacy have not been established) and breastfeeding mothers.
Conditional Use (Use with Caution)	Older adults, patients with mild to moderate renal or hepatic impairment, and individuals with a history of GI disease or controlled hypertension.

The regulatory profile mandates absolute prohibition for populations with specific severe organ failures and during late-stage pregnancy. All other high-risk groups are classified for restricted use, requiring caution and monitoring.

What should I know about interactions with other medicines?

The interaction profile of Ibupirac Flex involves considerations for both its components, Ibuprofen (a non-steroidal anti-inflammatory drug or NSAID) and Chlorzoxazone (a skeletal muscle relaxant).

Interactions with Ibuprofen (NSAID component):

Blood Thinners and Antiplatelet Agents: Concomitant use with anticoagulants (like warfarin) or antiplatelet drugs (like low-dose aspirin) is not recommended due to a significantly increased risk of serious gastrointestinal bleeding. Ibuprofen may also interfere with the antiplatelet effect of aspirin. If low-dose aspirin is required, it is generally recommended to take it at least two hours before ibuprofen.
Blood Pressure Medications and Diuretics: Ibuprofen may reduce the antihypertensive effect of Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-Blockers. It can also diminish the efficacy of diuretics (water pills) by affecting kidney function, potentially leading to fluid retention or worsening kidney function, particularly in older or volume-depleted patients.
Other NSAIDs: The combination with other NSAIDs (prescription or over-the-counter) is not advised as it increases the risk of serious side effects without providing additional benefit.
Lithium and Methotrexate: Ibuprofen can increase the blood levels and potential toxicity of both lithium and methotrexate by reducing their clearance from the body.

Interactions with Chlorzoxazone (Muscle Relaxant component):

Central Nervous System (CNS) Depressants: Chlorzoxazone's sedative properties are enhanced when used with alcohol or other CNS depressants, including tranquilizers, sleep aids, and some prescription pain relievers, potentially leading to increased drowsiness, dizziness, or impaired coordination.

Patients should inform a healthcare professional of all current medications, including herbal supplements, due to the complexity of these interactions.

Mechanism of Action

Ibupirac Flex is a fixed-dose combination product containing two active pharmaceutical ingredients: ibuprofen and orphenadrine (or clorzoxazone in some formulations). The product's overall pharmacodynamic action is the summation of these two distinct mechanisms.

Ibuprofen functions as a non-selective, reversible inhibitor of the cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2 (Prostaglandin G/H synthase 1 and 2). This molecular interaction prevents the conversion of the membrane lipid derivative, arachidonic acid, into unstable prostaglandin endoperoxides. This inhibition blocks the intracellular eicosanoid pathway, leading to a reduction in the synthesis of prostanoids, including prostaglandin E2 ( PGE2), prostacyclin ( PGI2), and thromboxane ( TxA2). This systemic reduction in prostanoid concentration modulates associated physiological cascades, including those governing vascular permeability and cellular signaling.

Orphenadrine (or clorzoxazone) acts primarily within the central nervous system. Orphenadrine is an antagonist at muscarinic acetylcholine receptors, which are distributed both centrally and peripherally. This interaction disrupts cholinergic neurotransmission, reducing the excitability of motor neurons and internuncial neurons in the spinal cord and subcortical regions. This modulation of central signaling pathways results in a reduction of efferent nerve impulses to skeletal muscle tissue. The resulting molecular and cellular changes lead to altered muscle spindle activity and subsequent modulation of skeletal muscle tone.

Dosage and Administration Information

Ibupirac Flex is administered exclusively via the oral route as a film-coated tablet, consistent with its design as a fixed-dose combination product containing Ibuprofen and Chlorzoxazone. The administration principle is governed by the need to maintain consistent therapeutic concentration.

Standard use involves taking the specified dose three or four times daily, corresponding to intervals typically ranging from every six to eight hours. The medicine is officially intended for short-term use for acute conditions. As an established principle of use, the dosage can usually be reduced as clinical improvement is noted. It is important to note that this medication is indicated as an adjunct (supplement) to other therapeutic measures, such as rest and physical therapy, rather than as a standalone treatment protocol.

Administration Conditions

The tablet should be swallowed whole with water and may be taken with or without food. Taking the dose with food or milk may be considered to reduce potential gastric irritation associated with the Ibuprofen component. In cases of a missed dose, the instruction is to skip the forgotten dose and resume the regular schedule, never taking a double amount to compensate. For older adults, prescribing principles suggest that a lower starting dosage or less frequent administration should be considered.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ibupirac Flex

Evidence for Use in Acute Musculoskeletal Pain with Spasm

The combination of Ibuprofen and Chlorzoxazone was studied for use in acute painful scenarios, particularly those conditions associated with acute or disruptive episodes where muscle contractures are present. Research has concentrated on adult patients experiencing short-duration pain, such as acute low back pain. The main types of research available include Randomized Controlled Trials (RCTs) and Systematic Reviews that evaluate the overall evidence landscape for this drug class.

Research examined outcomes related to physical discomfort, primarily measuring changes in pain intensity. Studies also monitored outcomes reflecting daily functioning or activity level. Some clinical trials reported that the combination was associated with greater changes in pain intensity measurements compared to Ibuprofen monotherapy over the short-term study period. However, broader systematic reviews note that data show patterns related to methodological variations and heterogeneity across different studies.

Long-term Follow-up and Duration of Study

The research on this combination primarily includes studies that were observed in defined and limited time intervals, typically focusing on periods of up to 7 days. These short-term studies are relevant in trials assessing short-term or episodic symptom patterns consistent with the acute nature of the condition it is studied for.

Because of the short duration of the available research, there is limited information for long-term outcomes beyond the initial acute phase. The studies contribute to understanding symptom patterns regarding short-term changes, but long-term effects are not fully established, meaning the durability of response and functional outcomes over many weeks or months are not well characterized.

What is Still Uncertain About the Research

Key research limitation frames include the fact that follow-up durations were limited in most pivotal trials. Additionally, evidence quality varies across studies, and methodological inconsistency is often noted when systematic reviews attempt to combine results from multiple trials. Research is ongoing in this therapeutic area, but the current findings describe group patterns, not personal outcomes, and the evidence highlights what is known — and what is still uncertain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Ibupirac Flex (FAQ)

Q: What is the difference between Ibupirac Flex and regular ibuprofen?

Ibupirac Flex is described in official product information as a fixed-dose combination product. It contains two active ingredients: ibuprofen, which works as a pain reliever and anti-inflammatory, and chlorzoxazone, which is a skeletal muscle relaxant. Regular ibuprofen products, by contrast, contain only ibuprofen.

Q: Why does this medicine include a 'Flex' component in the name?

The 'Flex' component is derived from the function of the chlorzoxazone ingredient. This compound is classified as a skeletal muscle relaxant, and its primary purpose is to help alleviate the muscle spasm and rigidity aspect of painful conditions.

Q: What kind of muscle soreness is Ibupirac Flex intended to help with?

Official indications state that this product is intended for the short-term treatment of acute musculoskeletal pain and spasm. This includes discomfort resulting from injuries like strains and sprains, particularly where involuntary muscle contraction (spasm) is contributing to the pain.

Q: How quickly does Ibupirac Flex typically start working?

Regulatory information indicates that both active ingredients are absorbed relatively quickly. Peak blood concentrations for the active components are generally observed within a time frame of one to two hours following administration.

Q: How long do the effects of Ibupirac Flex usually last?

The duration of effect is tied to the elimination of the active components from the body. Information regarding the chlorzoxazone component suggests that its half-life can support effects lasting for several hours, consistent with typical intervals for administration.

Q: Can Ibupirac Flex be taken for a headache or fever?

The combination product is primarily indicated for musculoskeletal pain associated with muscle spasm. While the ibuprofen component can help with pain and fever, the fixed-dose product is typically used for conditions that specifically require a muscle relaxant, not for simple headache or fever relief.

Q: Is it common to feel sleepy after taking Ibupirac Flex?

Yes, drowsiness (or sedation) is frequently reported as an adverse event. This is attributed to the presence of the chlorzoxazone component, which is a centrally-acting skeletal muscle relaxant that can affect the central nervous system.

Q: Is the 'Flex' component the reason why some people feel dizzy?

Yes, regulatory documents list dizziness as a commonly reported side effect. This effect is attributed to the action of the chlorzoxazone (muscle relaxant) component on the central nervous system.

Q: What are the most commonly reported side effects in official documents?

Commonly reported adverse events in clinical trials include effects on the nervous system, such as drowsiness and dizziness, as well as common gastrointestinal effects like nausea, stomach pain, and gastritis.

Q: What does official guidance say about taking Ibupirac Flex with food?

Official guidance notes that the medicine may be taken with or without food. Official guidance indicates that taking the medicine with food or milk may be useful for mitigating potential stomach irritation associated with the ibuprofen component.

Q: Are there any widely known non-prescription medicines that interact with Ibupirac Flex?

Yes, regulatory documents describe that concomitant use with other nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or naproxen is generally not recommended. Additionally, the sedative properties of the muscle relaxant component are known to be enhanced by alcohol.

Q: Are there any reported interactions with herbal supplements?

The chlorzoxazone component has reported interactions with certain herbal substances. For example, some sources mention that the combination should be used with caution alongside herbs like St John’s Wort, as this may increase the risk of certain side effects.

Q: Is Ibupirac Flex the same type of drug as naproxen?

The ibuprofen component is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), which is the same pharmacological class as naproxen. However, Ibupirac Flex is a combination product that also includes a skeletal muscle relaxant component, making its overall therapeutic action different.

Q: Why might a person use Ibupirac Flex instead of just acetaminophen?

The primary distinction is the medicine's dual action. Ibupirac Flex provides anti-inflammatory effects from ibuprofen and muscle-relaxing effects from chlorzoxazone. Acetaminophen (paracetamol) is a pain and fever reducer that lacks both the anti-inflammatory and muscle relaxant properties.

Q: Does the 'Flex' ingredient contribute to pain relief or muscle relaxation?

The component associated with the 'Flex' action, chlorzoxazone, contributes primarily to muscle relaxation. Its action helps reduce spasms and rigidity by affecting nerve impulses in the spinal cord, complementing the pain relief provided by the ibuprofen ingredient.

Q: Is there a maximum number of days Ibupirac Flex is typically intended for use?

The medication is intended for short-term use for acute conditions. Clinical guidelines are consistent with limited durations, such as those often described for the acute management of muscle spasms.

Q: Can Ibupirac Flex be used to treat menstrual cramps?

The combination product is officially indicated for acute musculoskeletal pain and spasm. Although the ibuprofen component is widely used for menstrual cramps, the combination product’s indication is focused on conditions requiring both an anti-inflammatory and a muscle relaxant.

Q: What types of allergic reactions are listed in official documents for Ibupirac Flex?

Official regulatory documents list the risk of severe allergic reactions. These can include symptoms such as hives, swelling of the face, tongue, or throat, difficulty breathing or wheezing, and severe skin reactions like rash and blisters.

Q: Can Ibupirac Flex affect blood pressure readings?

The ibuprofen component (an NSAID) is associated with warnings regarding the potential for developing or worsening existing high blood pressure (hypertension), which could impact blood pressure readings.

Q: Are there warnings about sun exposure while using Ibupirac Flex?

Ibuprofen is an NSAID, a drug class known to potentially increase the skin's sensitivity to sunlight (photosensitivity). Official product labeling usually advises checking for specific warnings regarding sun exposure while using the medication.

Q: Is there a risk of rebound headaches if Ibupirac Flex is used too frequently?

Frequent use of pain relievers, including NSAIDs like ibuprofen, has been associated with a risk of developing medication overuse headaches (MOH). Regulatory guidance advises limiting the duration of use to short-term to minimize this potential risk.

Q: What are the storage guidelines for Ibupirac Flex according to the manufacturer?

Official product information mandates that the medicine must be kept in its original container and stored in a cool and dry place at a temperature not exceeding 25 C. It must also be kept out of the sight and reach of children.

How should Ibupirac Flex be stored and disposed of?

How to Store and Dispose of Ibupirac Flex

To maintain the medication's stability, Ibupirac Flex must be stored in a cool and dry place at a temperature not exceeding 25°C.

Storage Requirements

The product must be kept in its original container and stored away from excess heat and moisture.
It is a mandatory safety requirement to keep the medicine out of the sight and reach of children.
The medicine must not be used after the expiration date printed on the packaging.

Disposal

Official regulatory guidance advises consulting a healthcare professional or pharmacist for proper disposal instructions regarding any unused or expired Ibupirac Flex tablets, in accordance with local environmental regulations.

Ibupirac Flex